MHLW Expert Panel on Comprehensive Policies

• Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
  June 7, 2023

• Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
  June 5, 2023

• Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
  June 5, 2023

• Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
  June 5, 2023

• Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
  April 28, 2023

• Expert Panel Questions Requirement for Generic Listing in All Versions
  April 5, 2023

• Expert Panel Mixed on Macroeconomic Indexing of Drug Cost; Govt Urged to Quit Targeting Pharma for Savings
  April 5, 2023

• Expert Panel Discusses 2% Buffer Zone, Member Floats “Regional Index”
  March 20, 2023

• Expert Panel Seeks Revision of Drug Pricing Rules to Stabilize Supplies
  March 20, 2023

• Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
  March 20, 2023

• Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
  February 16, 2023

• 5-Year Mandatory Stable Supply Rule for Generics under Scrutiny: Expert Panel
  February 16, 2023

• Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
  January 27, 2023

• Expert Panel Member Alarmed by Stagnation of Biosimilar Business in Japan
  January 27, 2023

• Experts Call for Deregulations for Orphan Support, English Dossiers to Foster Biotech Ecosystem
  January 16, 2023

• Add New Evaluation Elements in Granting Launch Premiums: Expert Panel
  December 12, 2022

• Market Expansion Re-Pricing Has Gone Overboard with Spillover Rule, Experts Say
  December 12, 2022

• Revisit PMP Company Criteria to Support Innovation from Foreign Biotechs: Experts
  December 12, 2022

• Experts Call for New Drug Pricing Rule for Innovative Medicines, No Objections Raised
  December 12, 2022

• Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
  October 31, 2022

ページ